Depressive Disorder News and Research

RSS

Clinical Data receives U.S. patent for vilazodone

Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.

16 Nov 2010

Study: Cognitive symptoms of depression cannot be discarded as risk factors for heart disease progression

Cognitive symptoms of depression cannot be simply discarded as risk factors for heart disease progression. When using a structured diagnostic interview, both somatic and cognitive symptoms of depression are associated with adverse cardiac outcome after adjusting for potential confounders.

11 Nov 2010

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.

8 Nov 2010

Effort exerted on cognitive task influenced by masked action or inaction cues

People may have a better memory for birthdays that are closer to their own: Volunteers recalling their friends' birthdays tended to remember birthdays that were closer to their own than birthdays that were farther away from their own birthday.

3 Nov 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

Researchers discover gene that contributes to depression

Yale University researchers have found a gene that seems to be a key contributor to the onset of depression and is a promising target for a new class of antidepressants, they report Oct. 17 in the journal Nature Medicine.

18 Oct 2010

AstraZeneca launches new campaign on depression through Facebook and Twitter

AstraZeneca is launching a new campaign called "Take on Depression" through a "Take on Depression" Facebook page and a @FaceDepression Twitter feed to support, educate, and inspire those affected by bipolar depression and major depressive disorder (MDD), also known as depression.

15 Oct 2010

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

Fisher Wallace Laboratories today announced the launch of a bold YouTube video campaign that challenges the pharmaceutical drug industry and introduces the company's easy-to-use medical device prescribed for the self-treatment of depression: the Fisher Wallace Cranial Stimulator.

6 Oct 2010

Researchers to conduct trial to improve drug abstinence, relapse rates

A $15.7 million award from the National Institute on Drug Abuse (NIDA) is allowing researchers to see whether consistent exercise will help people abstain from stimulant abuse.

6 Oct 2010

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

This study demonstrates that supplemental brief dynamic therapy in the treatment of patients with obsessive compulsive-disorder with concurrent major depressive disorder (who are receiving effective medication) has no significant clinical effect on both obsessive and depressive symptoms.

5 Oct 2010

Study finds children with ADHD have high risk for adolescent depression

Young children with attention-deficit/hyperactivity disorder (ADHD) appear to be at greater risk for adolescent depression and/or suicide attempts five to 13 years after diagnosis, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Oct 2010

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Depression treatment guidelines updated

There has been an update in the treatment of clinical depression. This includes suggestions on the use of medication, talk therapy, exercise, and alternative treatments and puts more emphasis on tailor made treatments for patients.

4 Oct 2010

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

8 Sep 2010

Research reveals need for initiatives to prevent, treat substance abuse when fighting violent crime

A new study from Sweden's Karolinska Institutet suggests that bipolar disorder or manic-depressive disorder does not increase the risk of committing violent crime. Instead, the over-representation of individuals with bipolar disorder in violent crime statistics is almost entirely attributable to concurrent substance abuse.

8 Sep 2010

Depressive Disorder News and Research

Clinical Data receives U.S. patent for vilazodone

Study: Cognitive symptoms of depression cannot be discarded as risk factors for heart disease progression

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

Effort exerted on cognitive task influenced by masked action or inaction cues

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Researchers discover gene that contributes to depression

AstraZeneca launches new campaign on depression through Facebook and Twitter

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

Researchers to conduct trial to improve drug abstinence, relapse rates

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

Study finds children with ADHD have high risk for adolescent depression

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

Depression treatment guidelines updated

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

Research reveals need for initiatives to prevent, treat substance abuse when fighting violent crime

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News